Back to 13F data
Healthcare

Nurix Therapeutics Inc

Nurix Therapeutics Inc is tracked here as a normalized 13F company record; no curated business description is available yet.

Original CUSIPs: 67080M103. This page shows current managers, quarterly changes, and primary SEC sources.

Current managers
1
Latest reporting quarter
Q1 2026

Who holds it and what changed this quarter

Portfolio weight and share-count changes are shown for every tracked manager with a current or prior-quarter position.

ARK Invest
Cathie Wood
Q1 2026
Increased
0.20% 0.21%

ARK Invest added 118,596 shares; portfolio weight moved from 0.20% to 0.21%.

+118,596 Shares
+7.40%
SEC05/12/2026

Four-quarter trend

Each line is one tracked manager’s portfolio weight. Labels identify the manager directly.

Historical and source details

Market values, quarterly totals, and original CUSIP rows are available below without obscuring current actions.

Quarterly holdings details
QuarterCurrent managersCombined valueTotal sharesManager details
Q2 20251$17,939,6111,575,032
ARK Invest New position · 1,575,032 Shares
Q3 20251$13,956,1331,510,404
ARK Invest Reduced · 1,510,404 Shares
Q4 20251$30,400,1711,602,539
ARK Invest Increased · 1,602,539 Shares
Q1 20261$26,677,5961,721,135
ARK Invest Increased · 1,721,135 Shares
Original CUSIP details
ManagerIssuerCUSIPSecurity classMarket valueSharesWeightSource
ARK InvestNurix Therapeutics Inc67080M103Common Stock$26,677,5961,721,1350.21%SEC XML